Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:2 Issue:7 Number:614 ISSN#:2563-5476
ACE Report #5106
Ace Report Cover Tumour

Ewing sarcoma treatment: assessment of cyclophosphamide and etoposide on survival rates

How to Cite

OrthoEvidence. Ewing sarcoma treatment: assessment of cyclophosphamide and etoposide on survival rates. ACE Report. 2013;2(7):614. Available from: https://myorthoevidene.com/AceReport/Report/5106

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients-

J Clin Oncol. 2008 Sep 20;26(27):4385-93. doi: 10.1200/JCO.2008.16.5720

Contributing Authors: M Paulussen AW Craft I Lewis A Hackshaw C Douglas J Dunst A Schuck W Winkelmann G Köhler C Poremba A Zoubek R Ladenstein H van den Berg A Hunold A Cassoni D Spooner R Grimer J Whelan A McTiernan H Jürgens European Intergroup Cooperativ

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


647 patients with localized Ewing sarcoma were sorted into two risk groups based on the stage and tumour volume. Patients were allocated to the standard-risk (SR) group if their localized tumours were less than 100 mL in volume. Patients with localized tumours greater than 100 mL or with metastatic disease were allocated to the high-risk (HR) group. The 155 SR patients were then randomized to rece...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.